4.6 Article

Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease

期刊

MOVEMENT DISORDERS
卷 34, 期 7, 页码 1006-1013

出版社

WILEY
DOI: 10.1002/mds.27730

关键词

iron; longitudinal; MRI; Parkinson's disease; quantitative susceptibility mapping; substantia nigra

资金

  1. Teva Neurosciences
  2. National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR001412]

向作者/读者索取更多资源

Background Parkinson's disease (PD) is characterized in part by the progressive accumulation of iron within the substantia nigra (SN); however, its spatial and temporal dynamics remain relatively poorly understood. Objectives The objective of this study was to investigate spatial patterns and temporal evolution of SN iron accumulation in PD. Methods A total of 18 PD patients (mean disease duration = 6.2 years) receiving dopaminergic therapy and 16 healthy controls were scanned with 3T MRI at baseline and 3 years later using quantitative susceptibility mapping, an indirect marker of iron content. Iron was assessed separately in the posterior SN and anterior SN at the ventral and dorsal levels of the SN. The results were corrected for the false discovery rate. Results A significant group effect was found for the ventral posterior SN (P < .001) and anterior SN (P = .042) quantitative susceptibility mapping as well as significant group x time interaction effects (P = .02 and P = .043, respectively). In addition, a significant intragroup change during 3 years of follow-up was found only in the ventral posterior SN of PD (P = .012), but not healthy controls. No significant effects were detected for any dorsal SN measures. No associations were identified with clinical measures. Conclusions We found both cross-sectional and longitudinal SN iron changes to be confined to its more ventral location in PD. Because pathology studies also show the ventral SN to degenerate early and to the greatest extent in PD, the assessment of iron levels by quantitative susceptibility mapping in this area may potentially represent a disease progression biomarker in PD. (c) 2019 International Parkinson and Movement Disorder Society

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据